Clinical

Here's a look at some of the most popular articles published in Evidence-Based Oncologyâ„¢ in 2016.

This week, the top stories in managed care include President Barack Obama signing the 21st Century Cures Act into law, findings from the CDC that opioid abuse has reduced life expectancy for Americans, and CVS announced a new program to lower costs for patients with diabetes.

At the Community Oncology Alliance (COA) Payer Exchange Summit V, panelists provided insights for successful implementation of payment models in oncology clinics.

What we're reading, December 15, 2016: Democrats won't help repeal the Affordable Care Act, but some may help pass a replacement; drug makers push new opioids despite lack of evidence they reduce overdoses; CDC issues Zika virus travel advisory for Texas town.

The guideline recommends that cancer patients should receive palliative care early and in parallel with their active treatment plan.

Paxman is seeking approval for using its scalp cooling device as an intervention to prevent chemotherapy-induced alopecia (CIA) in women undergoing chemotherapy treatment for breast cancer.

What we're reading, December 13, 2016: 1 in 6 American adults are prescribed psychiatric drugs; veterans groups want Donald Trump to keep the current Veterans Affairs secretary; and the number of drug-affected newborns is rising more in rural areas.

A study published in the Journal of Clinical Oncology has found that step therapy can be cost-effective in patients with cancer who are under psychological duress.

An exhaustive study conducted by researchers at the Kaiser Permanente Division of Research has found that a woman’s social network can significantly affect her chances of survival following breast cancer.

Palliative care is an underutilized and powerful resource in the drive towards value. In the current article, we review published evidence and highlight how Medicare Advantage plans, accountable care organizations, and oncology practices can benefit from concurrent palliative care under value-based payments.

The United States is in the midst of an opioid epidemic that has been responsible for a 200% increase in deaths due to overdose of heroin or an opioid pain reliever since 2000. Guidelines provide clinicians with ways to identify patients at risk of opioid use disorder and best practices of prescribing opioids.

By using telemedicine and relocating the center of care to where a person lives, we have an opportunity to address more unmet demand for palliative care, while giving more control to the seriously ill to meet their stated needs.

This week, the top stories in managed care included poll results that show growing numbers of Republicans want the Affordable Care Act scaled back instead of repealed, Jardiance received a new indication for patients with type 2 diabetes, and CareMore reported care coordination gaps for seniors.

This article examines the integration of palliative care in a community cancer center-an example of how one program integrated palliative care.

A panel of 21 expert clinicians from the field conducted a systematic review of meta-analyses randomized clinical trials, observational studies, and clinical experience, to develop recommendations that have been published in the Journal of Clinical Oncology.

What we're reading, December 7, 2016: health insurers provide demands if Republicans repeal Obamacare; women face 20% higher healthcare costs in retirement; and immunotherapies are being considered for sepsis.

Bundled payments are an interesting experiment, but they should have more clinically relevant time periods and include more quality measures, said Ashish K. Jha, MD, MPH, the K.T. Li Professor of Health Policy at the Harvard T.H. Chan School of Public Health and the director of the Harvard Global Health Institute.

In high-risk patients with chronic lymphocytic leukemia (CLL), CD19 chimeric antigen receptor (CAR) T-cells of defined composition can be administered with an acceptable early toxicity.

Representatives from the Beat acute myeloid leukemia (AML) and National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH), which incorporate genomic profiling to assign patients to different treatment arms, provided an insight on trial design and a progress report.

Older patients diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) continue to present a favorable response to single-agent ibrutinib, at a follow-up of 29 months, in phase 3 of the RESONATE-2 trial.

Pam Mangat, MS, associate director TAPUR study at the American Society of Clinical Oncology, says that the organization has developed a number of initiatives to educate oncology practitioners on the potential of precision medicine, such as testing guidelines, online courses, a virtual tumor board, and clinical trials.

Phase 3 results from the LyMa trial show that rituximab maintenance therapy after autologous stem cell transplant (ASCT) prolongs event-free survival, progression-free survival, and overall survival (OS) in previously untreated young patients with mantle cell lymphoma (MCL).

Early phase 1 results show that including the cyclin-dependent kinase 4/6 inhibitor palbociclib in the treatment of patients with mantle cell lymphoma (MCL) can help overcome resistance to ibrutinib.

Distinct genetic signatures can help distinguish responders from nonresponders of chimeric antigen receptor (CAR) T-cell treatment in patients diagnosed with chronic lymphocytic leukemia (CLL).

Chimeric antigen receptor (CAR) T-cells have been dramatically effective in treating B-cell cancers, according to David L. Porter, MD, of the University of Pennsylvania Health System. He also identified the use of CAR T-cells for treating solid tumors as a research area that will see more development in the coming years.

NICE recommends pembrolizumab for use in advanced lung cancer following additional data review and a further discount in price.

In an increasingly tech-focused world, the use of phones, tablets, and computes, combined with social media sites, have allowed patients to find the emotional and social interactions they need when dealing with their care, said Mike Payne, MBA, MSci, chief healthcare development officer at Omada Health.

Interim data analysis of a phase 1 trial of chimeric antigen receptor-T cells (CAR-T) targeting the B-cell maturation antigen in heavily pretreated patients with multiple myeloma has identified an objective anti-tumor response, with limited toxicity.

The PIONEER AF-PCI trial studied bleeding in patients with atrial fibrillation undergoing percutaneous coronary intervention with 3 different treatments. The study found that a rivaroxaban (Xarelto)-based strategy had a significant reduction of bleeding complications, explained Roxana Mehran, MD, FACC, FACP, professor of medicine and director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Weiner Cardiovascular Institute at Mount Sinai School of Medicine.

Statin use was associated with a reduction in all-cause and multiple myeloma-specific mortality.